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ABSTRACT 
 
Introduction: With advent of Anti Retroviral Therapy (ART) life of 
HIV positive patients has prolonged. In pre ART era survival proba-
bility of HIV patients was well studied but very few studies are 
d o c u m e n t e d  o n  s u r v i v a l  p r o b a b i l i t y  o f  H I V  p a t i e n t s  o n  A R T .  T h e  
current paper is an attempt to describe general profile of adult HIV 
patients and provide an estimate of survival probabilities following 
the time of diagnosis and initiation of antiretroviral therapy and its 
relation with WHO staging and CD4 count.  
Methodology: Analysis of secondary data of ART centre, New Civil 
Hospital, Surat, Gujarat, India was carried in January 2011. Individu-
als with age >15 years and had required information for analysis 
were included. Death of HIV patient was considered as outcome. 
Descriptive statistics to describe general profile, Kaplan Meier 
Method for survival probability and Log rank test for significance 
was used. Cox's proportional hazards used to look for association 
between variables and survival.  
Results: The proportions of males were 66%. Age group 25-45years 
contributes 77% of cases. Majority of patients were married (75%). 
Survival probability after 15 years of diagnosis of HIV was 83%. The 
4 year survival probability was 88% after the start of ART. The crude 
mortality rate was 8.6%. The mortality density was 10.8 per 1000 
person years. The marital status and gender were not associated with 
survival. WHO clinical staging 3 and 4, CD4 count <200, and age >55 
yrs have poor survival. There was significant difference in survival 
among different WHO clinical stages but no significant difference in 
survival between CD4 count 200 to 250, 250 to 350, 350 to 500 and 
>500.  
Conclusion: The new WHO guideline to start ART when CD4 count 
is <350 can cause financial burden to provide free ART without 
survival advantage.  
 
Key words: HIV, Anti Retroviral Therapy, Survival, CD4 count, 
WHO staging 
 
INTRODUCTION 
The "3 by 5" initiative, launched by United 
Nations Programme on HIV/AIDS (UNAIDS) 
and World Health Organization (WHO)  in 2003, 
was a global target to provide three million 
people living with HIV/AIDS in low- and mid-
dle-income countries with life-prolonging antire-
troviral treatment (ART) by the end of 2005. (1) 
Demographically the second largest country in 
the world, India has also the third largest num- 
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ber of people living with HIV/AIDS. As per the 
provisional HIV estimate of 2008-09, there are an 
estimated 22.7 lakh people living with 
HIV/AIDS in India. The HIV prevalence rate in 
the country is 0.29 percent (2008-09).  (2) Gujarat 
State is estimated to have more than 1 lakh 
People Living with HIV/AIDS (PLHA). (3) The 
primary goal of ART is it prolongs lives, making 
HIV/AIDS a chronic disease, not a death sen-
tence. (1) As of April 2011 in Gujarat 22 Anti 
Retroviral Therapy (ART) centers are functional. 
At the end of May ’11, patients ever registered 
are 61847, out of which 21259 patients are alive 
and taking treatment on ART. In addition, 259 
patients are taking second line ART at Centre of 
Excellence (COE), Ahmedabad & Surat. Alter-
n a t e  r e g i m e  o f  A R T  i s  b e i n g  p r o v i d e d  t o  3 7 2  
patients.  (3) There is little evidence regarding 
survival probabilities in HIV-infected patients in 
Gujarat particularly and India by large due to the 
lack of prospective studies. This study investi-
gated survival probability both after initial HIV 
diagnosis and start of ART in HIV/AIDS pa-
tients on ART. 
 
OBJECTIVES 
Objective of this study was to describe the gen-
eral profile of adult HIV patients registered at 
ART centre, NCH, Surat and to provide an 
estimate of survival probabilities of adult HIV 
patients following the time of diagnosis and also 
following initiation of antiretroviral therapy. 
 
METHODOLOGY 
Study setting: Surat city and district, with max-
imum migrant workers and floating population, 
has the highest number of AIDS patients in the 
Gujarat state. Currently, in National AIDS Con-
trol Programme (NACP) Phase III, Surat district 
belongs to the Category A of risk categories for 
HIV/AIDS.(4) The ART centre at New Civil 
Hospital Surat has been established in the year 
2006 and 5,422 HIV-infected individuals are 
registered with the ART Centre since September 
2006 until December 2010. It is the nodal center 
for providing ART and care to the PLHA and 
newly diagnosed HIV positive in the entire 
South Gujarat. Secondary data analysis of the 
data was done in January 2011. 
Selection Criteria: For general profile the data of 
all the individuals with age >15 years were 
included for description. The data of individuals 
who had information regarding HIV diagnosis 
date, baseline WHO staging and CD4 count, date 
when ART was started and ART centre, Surat as 
the first centre of registration were included for 
survival analysis. 
Sample size: Out of the total 5,422 HIV-infected 
individuals registered with the ART Centre since 
September 2006 until December 2010, 5230 
patients were with age ≥15 years and on ART, 
the secondary data of which was analyzed in the 
current study  
Outcome Measure: Death of a HIV patient was 
taken as the primary end point. 
Statistical Analysis: The use of descriptive 
statistics was done to describe general profile of 
the patients. The survival probability was calcu-
lated using Kaplan Meier Method for survival 
probability and Log rank test was used to define 
the significance of the survival analysis. The 
regression analysis using Cox's proportional 
hazards was done to look for association be-
tween variables and survival. Software:  The 
analysis was performed using SPSS Version 16. 
Ethical clearance was taken from Human Re-
search Ethics Committee, Government Medical 
College, Surat. 
 
RESULTS 
Out of the total 5,422 HIV-infected individuals 
registered with the ART Centre since September 
2006 until December 2010, 5230 patients were 
with age ≥15 years and on ART (Table 1). The 
mortality density is 10.8 per 1,000 person years. 
The proportions of males (66%) were more but 
sex wise proportion of deaths was similar (males 
8.7%, females 8.4%). The age groups between 25-
45 years contribute to 77% of cases. The propor-
tion of deaths is more as the age advances and 
maximum after 55 years. The marital status data 
of 4921 patients was available. Out of which 
majority of the patients were married (75%) and 
proportion of deaths among married was 7.9%, 
9.7% among unmarried and 8.1% among conflict 
marital status.  
The baseline CD4+ count of 4671 patients was 
available. Out of which the proportion of pa-
tients (66.5%) and the deaths (10.5%) is high in 
patients with CD4+ count <200. Only 2918 
patients’ baseline WHO staging was available. 
Majority of the patients are registered at ART 
center with WHO stage 2 (33%) and Stage 3 
(30%). The proportion of deaths is more in Stage 
4 patients (22%) and next to it is Stage 3 (14%).  
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Table 1: Characteristics of study population 
Categories  All (%)  Deaths (%)  Mortality density 
No.* Deaths Person 
years 
Mortality density 
(per 1,000 person yrs) 
Total Individuals (≥15 years age)  5230 448  (8.6)  3608  117  10830  10.8 
Sex            
Male 
Female 
3445 (65.9) 
1785 (34.1) 
298 (8.7) 
150 (8.4) 
2348 
1260 
75 
42 
7052 
3778 
10.7 
11.1 
Age (years)            
15-24 
25-34 
35-44 
45-54 
>55 
292 (5.6) 
1918 (36.7) 
2102 (40.2) 
689 (13.2) 
229 (4.4) 
18 (6.2) 
123 (6.4) 
186 (8.8) 
85 (12.3) 
36 (15.7) 
190 
1339 
1438 
497 
144 
4 
30 
48 
25 
10 
492 
4079 
4492 
1384 
383 
8.1 
7.4 
10.7 
18.1 
26.2 
Marital Status (n=4921)**            
Married 
Unmarried 
Conflict# 
3677 (74.7) 
350 (7.1) 
894 (18.2) 
290 (7.9) 
34 (9.7) 
72 (8.1) 
2666 
249 
640 
77 
12 
25 
7950 
678 
2073 
9.7 
17.7 
12.1 
CD4+T-cell counts (n=4671)**            
<200 
200-250 
250-350 
350-500 
>500 
3104 (66.5) 
641 (13.7) 
459 (9.8) 
267 (5.7) 
200 (4.3) 
325 (10.5) 
29 (4.5) 
26 (5.7) 
16 (6.0) 
4 (2.0) 
2031 
467 
337 
188 
141 
81 
10 
9 
4 
2 
6011 
1370 
1180 
852 
714 
13.5 
7.3 
7.6 
4.7 
2.8 
WHO Staging (n=2918)**            
1 
2 
3 
4 
687 (23.5) 
964 (33.0) 
885 (30.3) 
382 (13.1) 
30 (4.4) 
68 (7.1) 
122 (13.8) 
84 (22.0) 
438 
544 
477 
175 
6 
10 
6 
6 
2167 
2321 
1787 
665 
2.8 
4.3 
3.4 
9.0 
Referral            
Direct 
Transfer in 
3824 (73.1) 
1406 (26.9) 
377 (9.9) 
71 (5.0) 
2603 
1005 
99 
18 
6382 
4448 
15.5 
4.1 
ART Regimen (n=3090)**            
SLN@ 
ZLN 
SLE 
ZLE 
801 (25.9) 
1719 (55.6) 
217 (7.0) 
353 (11.4) 
96 (12.0) 
140 (8.1) 
32 (14.7) 
46 (13.0) 
454 
988 
110 
183 
7 
15 
1 
6 
2149 
4167 
423 
760 
3.3 
3.6 
2.4 
7.9 
*Includes only individuals whose date of diagnosis was available; **Data of other individuals missing and does not include 
individuals on 2nd line ART;  #Includes Divorce (Cases:113; Deaths:16) Separated (Cases:30; Deaths:2) Widow/er (Cases:739; 
Deaths:52), Live in (Cases:12;Deaths:2);  @ S; Stavudine, L; Lamivudine, N; Nevirapine, E; Efavirenz 
 
The patients with ART center Surat as the center 
of first contact were 73% and transfer in patients 
were 27%. Proportion of deaths was more among 
direct (10%) than transfer in (5%) patients. Out of 
the 3090 patients whose initial ART regimen was 
available majority of the patients were put on 
ZLN (56%) ART regimen. 
Out of 5230 adult HIV patients registered at ART 
center Surat, 3824 patients were not referred 
from any center but ART center Surat was the 
first center of contact. Out of those 3824 patients, 
the date of HIV diagnosis was available for 2603 
patients, whose survival probability after HIV 
diagnosis was estimated (Fig.1). The survival 
probability after I year of diagnosis of HIV and 
have taken ART at some point of time is 98% and 
it is 93% after 5 years. The median follow up 
period was 2.46 years. 
Fig.1: Survival probability after HIV diagnosis 
(n=2603) 
  
 
Open Access Article│www.njcmindia.org    pISSN 0976 3325│eISSN 2229 6816 
National Journal of Community Medicine│Volume 4│Issue 2│Apr – June 2013  Page 204 
 
 
Fig.2: Survival probability after start of ART 
(n=3263) 
 
 
Out of 3824 adult patients with ART center Surat 
as the first center of contact 150 patients had 
either no date of start of ART or they died on the 
day of start of ART and 411 had no data on 
baseline CD4+ count.  So the survival probability 
after start of ART was estimated on remaining 
3263 patients (Fig.2). The overall median follow-
up was 16 months (interquartile range, 8-29 
months). The survival probability after 6 months 
of start of ART is 92%, 91% after 1 year and 88% 
at third and fourth year. 
The stratified Kaplan Meier survival analysis of 
3263 patients showed that the survival probabili-
ty was different among different age groups, 
patients with different CD4+ count and with 
different WHO staging (n=1902 patients data 
was available) and the difference was statistically 
significant (p <0.001). The difference in survival 
probability for male or female sex (p = 0.557) and 
differential marital status (p = 0.136) were statis-
tically insignificant (Figure 3). 
 
Fig. 3: Survival after start of ART stratified by various characteristics A. Age; B. Sex; C. Marital 
Status; D. CD4+ count; E. WHO staging 
A     -   A g e       B   -   S e x  
        
C – Marital Status          D – CD4+ count 
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E – WHO Staging 
 
Table 2: 4 yr survival probability following start of ART and estimated hazard ratios for variables 
Variables Categories  Cases 
(n = 3263) 
Survival probability
after 4  years  
Hazard Ratio (95% CI)  p value 
Age (years)  15-25 
25-35 
35-45 
45-55 
>55 
199 
1227 
1282 
420 
135 
91.7 
90.7 
88.0 
82.0 
77.2 
0.3680 (0.1811 – 0.7480) 
0.4219 (0.2623 – 0.6786) 
0.5144 (0.3228 – 0.8197) 
0.7654 (0.4623 – 1.2672) 
1.0 
0.0057 
0.0004 
0.0052 
0.2986 
- 
Marital Status  Married 
Unmarried 
Conflict 
2362 
239 
662 
84.2 
88.4 
88.3 
0.8877 (0.6667 - 1.1821) 
1.3164 (0.8367 - 2.0711) 
1.0 
0.4151 
0.2344 
- 
CD4+T-cell counts  <200 
200-250 
250-350 
350-500 
>500 
2463 
481 
209 
64 
46 
87.1 
92.5 
83.6 
91.3 
100.0 
1.0 
0.4833 (0.3125 - 0.7477) 
0.8435 (0.5085 - 1.3992) 
0.4409 (0.1412 - 1.3763) 
0.0 
- 
0.0011 
0.5098 
0.1585 
0.9768 
WHO Staging (n=1902)  1 
2 
3 
4 
225 
664 
707 
276 
96.5 
92.3 
85.1 
76.0 
1.0 
2.1170 (0.9966 - 4.4967) 
4.3144 (2.0942 - 8.8883) 
7.0969 (3.3832 - 14.8874) 
- 
0.051 
0.0001 
<0.0001 
 
Table 3: Comparison within WHO staging and CD+ Count (After start of ART) 
Variable Patients Deaths  Kaplan-Meier  Survival  Analysis: 
Comparison of groups using Log Rank test 
WHO Staging (n=1902) 
   1  255  8 
P = <0.001 
P = 0.045 
      
   2  664  44 
P = <0.001 
   
   3  707  91   
P = 0.003 
  
   4  276  56         
CD4+ Count (n = 3263) 
   <200  2463  247 
P = 0.001 
P = 0.001 
      
   200-250  481  22 
P = 0.071 
  
P = 0.147     250-350  209  16   
P = 0.172 
 
   350-500  64  3     
P = 0.137 
   >500  46  0         
Age Group (n = 3263) 
   15-25  199  12 
P = <0.001 
P = 0.624 
    
P = 0.263     25-35  1227  90 
P = 0.162 
  
   35-45  1282  113   
P = 0.015 
 
   45-55  420  54     
P = 0.272 
 
   >55  135  21         
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When calculated for different categories of age 
groups, the Cox proportional hazard was less 
among all age groups less than 45 years as com-
pared with age group more than 55 years. The 
difference was statistically significant (Table 2). 
The hazard ratio of CD4+ count >200 is less as 
compared to CD4+ count <200. Among the 
WHO staging the hazard ratio is maximum for 
stage 4 (HR 7.0969, p <0.001). 
Comparison within the WHO staging (Table 3) 
showed statistically significant difference in each 
group. The difference in survival probability 
between CD4+ count <200 and 200-250 is statisti-
cally significant (p = 0.001) but there is no statis-
tical significant difference between the groups 
250-350, 350-500 and >500. (p = >0.05) The differ-
ence in survival probability between age groups 
15-25, 25-35 and 35-45 is insignificant. (p=>0.05). 
 
DISCUSSION 
The survival probability after 15 years of diagno-
sis of HIV is 83%. The 4 year survival probability 
is 88% after the start of ART. The crude mortality 
rate is 8.6%. The Robert S. Hogg et al reported 
crude mortality of 33.1% in their study in 1998. (5) 
With time the awareness of HIV may be in-
creased leading to early initiation of ART and 
good adherence and decline in mortality due to 
HIV.  (5)  The mortality density per 1000 person 
years in the current study and Mee-Kyung Kee et 
al  (6) are 10.8 and 45.7 respectively. Mee-Kyung 
Kee et al (6) and Arif Alibhai et al (7) reported 
higher survival among women but the role of 
gender as predictor of survival could not be well 
established in the present study. The marital 
status as a social factor does not significantly 
contribute to survival. Mee-Kyung Kee et al and 
current study have the same opinion that the age 
>55 years, CD4+ count <200 and WHO stage 3 
and 4 have poor survival. As the age more than 
55years has come out as an independent risk for 
poor survival. It may be due to the delayed 
diagnosis or due to the aging itself. The study 
suggests considering old age as one of the crite-
ria in deciding start of ART in HIV individuals.  
 
Table 4: Initiation of ART based on CD4 count and WHO clinical staging* (8) 
Classification of HIV 
associated clinical disease 
WHO 
Clinical stage 
According to CD4 count  
(NACO and WHO 2006 guidelines) 
According to CD4 count 
(WHO 2010 guidelines) 
Asymptomatic 1 
Treat if CD4 <200  Treat if CD4 <350 
Mild symptoms  2 
Advanced symptoms  3  Consider treatment if CD4 <350 and 
 initiate ART before CD4 drops below 200 
Treat irrespective of CD4 
 count 
Severe/Advanced sympt.  4  Treat irrespective of CD4 count 
*Antiretroviral Therapy Guidelines for HIV-infected Adults and Adolescents Including Post-exposure Prophylaxis, NACO, 
May 2007 
 
NACO guidelines as when to start is based on 
2006 WHO guidelines on ART. The 2010 WHO 
has recommended new guidelines for ART with 
different CD4 cut off to start ART. The NACO is 
trying to adopt the new guidelines. ART Accord-
ing to the NACO guidelines (which is based on 
2006 WHO guidelines) ART is initiated depend-
ing upon the WHO stage of infection. PLHA 
with less than 200 CD4 (while blood cells/ mm3) 
require treatment irrespective of the clinical 
stage. For PLHA with 200-350 CD4, ART is 
offered to symptomatic patients. Among those 
with CD4 of more than 350, treatment is deferred 
for asymptomatic persons. In the 2010 WHO 
guidelines the cut off for asymptomatic persons 
has been raised from 200 to 350. (9)  
 
CONCLUSIONS 
The current survival analysis shows that at CD4 
count less than 200 there is significant difference 
in survival in comparison with the higher CD4 
counts. Above the CD4 count 200 there is no 
statistical significance in survival between vari-
ous cut off. So it doesn’t matter when survival is 
considered, whether CD4 count is 350 or 250 
unless it is less than 200 to start ART. But the 
survival is statistically significant within the 
WHO clinical staging. So to start ART it matters 
whether the patient is in Stage 1, 2, 3 or 4 for 
survival. The current study therefore supports 
that when CD4 count testing facility is not avail-
able WHO staging is to be the deciding factor to 
start ART. But when facility is available then for 
asymptomatic patients cut off of 200 is still 
preferred rather than 350 of new WHO guide-
lines. The cut off 200 can deprive ART for pa-
tients on borderline risk i.e. with CD4 count 
between 200 and 250. The cut off 350 is too high 
so that many patients need to be put on ART. It 
will not have any survival advantage rather will 
be financial overburden to the state.   
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RECOMMENDATIONS 
The study recommends for asymptomatic pa-
tients and symptomatic stage 1 and 2 patients the 
ART should be considered when CD4 count is 
below 250 and irrespective of CD4 count for 
Stage 3 and 4 patients. The data should be fur-
ther analysed using regression model to identify 
the most important predictor of survival. 
 
Limitations 
The analysis does not take into consideration the 
associated opportunistic infection neither at the 
time of diagnosis nor at the time of start of ART.  
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